CL

Business Context and Reporting Period

Company: Colgate-Palmolive Company
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2004
Business Overview: The Company operates in two primary segments: Oral, Personal and Home Care (divided into North America, Latin America, Europe, and Asia/Africa) and Pet Nutrition (Hill's). The Company competes in over 200 countries and territories.

Key Financial Metrics

(Dollars in Millions, except per share data)

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 4.5% in Q2 2004 and 5.8% in the first six months compared to 2003. Growth was driven by unit volume gains (4.0% in Q2) and favorable foreign exchange impacts (1.5% in Q2), partially offset by net selling price decreases.
• Profitability: Operating profit increased 5% in both Q2 and the first six months. Net income rose 4% in both periods. Diluted EPS increased 6% year-over-year.
• Acquisition Impact: The acquisition of GABA Holding AG (completed June 1, 2004) contributed 0.5% to worldwide sales growth in Q2. Pro forma data suggests GABA would have increased sales by approximately 2% prior to acquisition.
• Divestitures: The Company sold detergent businesses in Ecuador and Peru in June 2004, recognizing a pre-tax gain of $26.7 million. It also agreed to sell its Colombian detergent business.
• Working Capital: Net cash provided by operations decreased to $644.0 million (six months 2004) from $730.3 million (six months 2003), primarily due to higher cash tax payments and increased inventory levels.

Guidance, Outlook, and Risks

• Outlook: Management anticipates incremental borrowings related to the GABA acquisition will be repaid within 12 months due to strong cash flow and a projected decline in share repurchases in the second half of 2004. The full-year effective income tax rate is estimated at 32.7%.
• Restructuring: The Company is realigning manufacturing operations and implementing workforce reductions in Europe, Latin America, and Asia/Africa. Total restructuring costs for 2004 are expected to be approximately $70 million. Additional incremental depreciation of approximately $4 million is expected in 2004.
• Legal Contingencies:
  • Brazil: Significant ongoing proceedings involving the Central Bank of Brazil (fine approx. $85 million) and tax authorities (assessment approx. $40 million) regarding the 1995 Kolynos acquisition. Criminal charges were authorized against certain officers in February 2004. Management intends to defend vigorously and believes the ultimate disposition will not have a material impact.
  • IRS: An administrative appeal is pending regarding tax deductions for expatriate executive compensation for tax years 1996-1998.
• Retirement Benefits: The Company will adopt FSP FAS 106-2 in Q3 2004 regarding the Medicare Part D subsidy, expected to reduce the accumulated postretirement benefit obligation by approximately $15 million and annual benefit cost by $2 million.

Investor Verification Checklist

• GABA Integration: Verify the final purchase price allocation and the realization of projected synergies from the GABA acquisition.
• Brazilian Legal Exposure: Monitor the status of the Central Bank fine, tax assessments, and criminal proceedings in Brazil, as these represent significant contingent liabilities.
• Restructuring Execution: Track the completion of manufacturing regionalization and workforce reductions to ensure the projected $70 million total cost is accurate.
• Working Capital Trends: Assess whether the increase in inventory levels is temporary (due to new product launches) or indicative of a longer-term trend affecting cash flow.
• Debt Refinancing: Confirm the Company's ability to refinance commercial paper and current maturities as intended to maintain liquidity ratios.